Hematological toxicity of adjuvant portal liver infusion with fluorouracil, mitomycin and heparin

Anticancer Res. 1991 Jan-Feb;11(1):365-8.

Abstract

Adjuvant perioperative liver infusion chemotherapy with fluorouracil, mitomycin and heparin caused mild but significant myelosuppression in the first two postoperative weeks. This was associated with a slightly increased bleeding tendency. Mortality was not increased. Future trials might combine chemotherapy with hematopoietic growth factors in order to minimize myelosuppression.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / toxicity*
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / surgery
  • Combined Modality Therapy
  • Female
  • Fluorouracil / administration & dosage*
  • Fluorouracil / toxicity
  • Follow-Up Studies
  • Hemoglobins / drug effects
  • Heparin / administration & dosage*
  • Heparin / toxicity
  • Humans
  • Infusions, Intravenous
  • Leukocyte Count / drug effects*
  • Male
  • Mitomycin
  • Mitomycins / administration & dosage*
  • Mitomycins / toxicity
  • Platelet Count / drug effects*
  • Portal Vein
  • Random Allocation
  • Rectal Neoplasms / drug therapy*
  • Rectal Neoplasms / pathology
  • Rectal Neoplasms / surgery

Substances

  • Antineoplastic Agents
  • Hemoglobins
  • Mitomycins
  • Mitomycin
  • Heparin
  • Fluorouracil